Ultragenyx to Present at Morgan Stanley Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Morgan Stanley 19th Annual Healthcare Conference on September 14, 2021, at 4:15 PM ET. The presentation will be available via a live and archived webcast on the company’s website, with the replay accessible for 90 days. Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, emphasizing novel products with high unmet medical needs. The company aims for efficient drug development to deliver urgent solutions to patients.
- None.
- None.
NOVATO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President will present at the Morgan Stanley 19th Annual Healthcare Conference on September 14, 2021 at 4:15 PM ET.
The live and archived webcast of the presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-660-0951
Media
Carolyn Wang
415-225-5050
FAQ
When will Ultragenyx Pharmaceutical present at the Morgan Stanley Healthcare Conference?
Where can I watch the Ultragenyx conference presentation?
What is the focus of Ultragenyx Pharmaceutical?
How long will the Ultragenyx presentation replay be available?
What is the stock symbol for Ultragenyx Pharmaceutical?
